Zoomedia to Participate as an Expert Consultant in Partnering for Cures Meeting in NYC, Nov 6-8
We will be participating at this year’s Partnering for Cures meeting as part of the Expert Consultation track, intended to provide meeting participants with access to strategic, top-line guidance in areas such as organizational planning, research operations, and implementation of new collaborations. I will be consulting on Communications and Marketing. Other categories include Strategic Planning, Deal Structuring and Development.
For meeting participants, the benefit will be access to brief, private meetings with leading issue-area experts from a variety of technical, scientific and financial backgrounds.
Of course, all this is to facilitate knowledge sharing as part of the FasterCures mission to advance common goals and bring patients new treatments more efficiently. If you’re interested in participating or in learning more, please don’t hesitate to contact me or see the meeting website www.partneringforcures.org.
About Partnering for Cures
For all the human and financial capital flowing through our health system, there remains a formidable list of diseases for which there are no cures or even meaningful treatment options. But the search for cures cannot happen in a vacuum.
FasterCures, the Washington, DC-based center of the Milken Institute, is convening the third annual Partnering for Cures meeting on November 6-8, 2011 in New York City.
This effort brings together medical research leaders and decision-makers, innovators, and advocates from across sectors to find workable solutions that will expedite the medical research and development process.
Objectives
- Convene distinct sectors of the medical research enterprise to identify partnership opportunities that will advance outcomesâdriven medical research.
- Catalyze a more effective and efficient medical research enterprise through more strategic and timely allocation of critical resources.
- Cultivate cross-sector relationships that will lead to collaborative efforts necessary for the commercialization of new therapies.




